Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas

Zachary Braunstein; Miguel Ruiz; Walter Hanel; Polina Shindiapina; John C Reneau; Jonathan E Brammer

doi:10.3390/jpm12060964

Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas

J Pers Med. 2022 Jun 13;12(6):964. doi: 10.3390/jpm12060964.

Authors

Zachary Braunstein¹, Miguel Ruiz¹, Walter Hanel², Polina Shindiapina², John C Reneau², Jonathan E Brammer²

Affiliations

¹ Wexner Medical Center, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
² James Comprehensive Cancer Center, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.

Abstract

Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed/refractory PTCL.

Keywords: T cell; adult T-cell lymphoma; angioimmunoblastic T-cell lymphoma; leukemia; lymphoma; novel therapy; peripheral T-cell lymphoma; peripheral T-cell lymphoma not otherwise specified; refractory; relapsed; therapeutics.

Publication types

Review

Grants and funding

This research received no external funding.